Skip to search formSkip to main contentSkip to account menu

glutathione analog

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

peptide analog

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 764: GSTP1 knockdown and inhibition impairs pancreatic ductal adenocarcinoma (PDAC) growth
Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related mortalities in the Western world and… 
2005
2005
TLK286, a novel glutathione analog prodrug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells
1500 The development of resistance to platinum drugs has limited their efficacy and is an important clinical problem. The… 
2005
2005
Prevention of carboplatin-induced resistance in human ovarian tumor xenografts
1497 The development of drug resistance is a major problem in cancer chemotherapy. Most attempts to circumvent resistance have… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC)
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1–1, which is overexpressed in NSCLC… 
2004
2004
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer.
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1-1, which is overexpressed in ovarian cancer… 
2004
2004
Phase 1–2a dose ranging study of TLK286 (a novel glutathione analog) in combination with liposomal doxorubicin in platinum refractory or resistant ovarian cancer
5062 Background: TLK286 (Telcyta) is a glutathione analog prodrug activated by GST P1–1, which is overexpressed in ovarian cancer… 
2004
2004
Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
7140 Background: TLK286 (Telcyta) is a novel glutathione analog prodrug activated by GST P1-1, which is overexpressed in NSCLC… 
2003
2003
Phase I Study of TLK 286 ( Glutathione S-Transferase P 1-1 Activated Glutathione Analogue ) in Advanced Refractory Solid Malignancies 1
Purpose: The purpose of this study was to determine the dose-limiting toxicities (DLTs), the maximum tolerated dose, and the… 
2003
2003
O-287 Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with platinum refractory of resistant non-small cell lung cancer (NSCLC)
1993
1993
Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats.
Effects of YM737[N-(N-r-L-glutamyl-L-cysteinyl)glycine 1-isopropyl ester sulfate monohydrate], a new glutathione (GSH) analog… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)